Roche Sales Grow, Buoyed by New Drugs
October 17 2018 - 1:46AM
Dow Jones News
By Donato Paolo Mancini
Swiss pharmaceuticals giant Roche Holding AG (ROG.EB) said
Wednesday that its nine-month group sales rose on year.
The Basel, Switzerland-based company said its nine-month group
sales rose to 42.08 billion Swiss francs ($42.55 billion) up from
CHF39.43 billion the year before.
In the pharmaceuticals division, sales rose to CHF32.70 billion,
up from CHF30.63 billion the year before.
Roche said sales were boosted by Ocrevus, which is used to treat
two forms of multiple sclerosis, and cancer medicines Perjeta,
Alecensa and Tecentriq. The company said the increase was partially
offset by lower sales of MabThera/Rituxan and Tarceva.
Roche backed its outlook for the year after raising it twice in
2018. It expects sales to grow in mid-single digits, at constant
exchange rates. It also expects to further increase its dividend in
Swiss francs.
"In the first nine months of the year, both our pharmaceuticals
and diagnostics divisions achieved very strong sales growth. The
uptake of our new medicines continued to be strong in the third
quarter," said Roche Chief Executive Severin Schwan. "Based on the
performance in the first nine months of the year, we will achieve
our full-year targets."
Write to Donato Paolo Mancini at
donatopaolo.mancini@dowjones.com
(END) Dow Jones Newswires
October 17, 2018 01:31 ET (05:31 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024
